Can-Fite BioPharma
Can-Fite BioPharma
CANF
NYSE
0.01
USD
-99.31%
About
Can Fite Biofarma Ltd is an Israel-based clinical-stage biopharmaceutical company engaged in developing orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. The Company co-develop formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases.
It's technology utilizes the Gi protein associated A3AR as a therapeutic target. A3AR is expressed in inflammatory and cancer cells, and not significantly expressed in normal cells, suggesting that the receptor could be a target for pharmacological intervention..
Financials Amount (in millions)
Income statement
Balance sheet
Cash flow
Ratios
| Price and Volume | |
|---|---|
| Volume | |
| Ten Day Average Volume | 5.1M |
| Three Month Average Volume | 195.1M |
| High Low | |
| Fifty-Two Week High | 0.01546 USD |
| Fifty-Two Week Low | 0.0069 USD |
| Fifty-Two Week High Date | 22 Jul 2024 |
| Fifty-Two Week Low Date | 21 Apr 2024 |
| Price and Volume | |
| Current Price | 0.00828 USD |
| Beta | 1 |
| Relative Price Change | |
| Four Week Relative Price Change | -27.30% |
| Thirteen Week Relative Price Change | 6.40% |
| Twenty-Six Week Relative Price Change | 9.81% |
| Fifty-Two Week Relative Price Change | -23.02% |
| Year-to-Date Relative Price Change | 4.60% |
| Price Change | |
| One Day Price Change | 0.00% |
| Thirteen Week Price Change | 11.11% |
| Twenty-Six Week Price Change | 15.38% |
| Five Day Price Change | -3.23% |
| Fifty-Two Week Price Change | -14.29% |
| Year-to-Date Price Change | 15.38% |
| Month-to-Date Price Change | -25.00% |
| Per Share Data | |
|---|---|
| Book Value | |
| Book Value Per Share (Last Fiscal Year) | 0.00459 USD |
| Book Value Per Share (Most Recent Quarter) | 0.00148 USD |
| Tangible Book Value Per Share (Last Fiscal Year) | 0.00459 USD |
| Tangible Book Value Per Share (Most Recent Quarter) | 0.00148 USD |
| EBITD | |
| EBITD Per Share (Trailing Twelve Months) | -0.00516 USD |
| Revenue | |
| Revenue Per Share (Last Fiscal Year) | 0.00058 USD |
| Revenue Per Share (Trailing Twelve Months) | 0.00044 USD |
| Dividend | |
| Dividend Per Share (Last Fiscal Year) | -27610.21013 USD |
| Dividend Per Share (Trailing Twelve Months) | 0 USD |
| Dividend Per Share (5 Year) | -27610.21013 USD |
| Earnings Per Share | |
| Excluding Extraordinary Items (Last Fiscal Year) | -0.00597 USD |
| Excluding Extraordinary Items (Trailing Twelve Months) | -0.00472 USD |
| Normalized (Last Fiscal Year) | -0.00597 USD |
| Basic Excluding Extraordinary Items (Last Fiscal Year) | -0.00597 USD |
| Basic Excluding Extraordinary Items (Trailing Twelve Months) | -0.00472 USD |
| Including Extraordinary Items (Last Fiscal Year) | -0.00597 USD |
| Including Extraordinary Items (Trailing Twelve Months) | -0.00472 USD |
| Cash | |
| Cash Per Share (Last Fiscal Year) | 0.00316 USD |
| Cash Per Share (Most Recent Quarter) | 0.00283 USD |
| Cash Flow Per Share (Last Fiscal Year) | -0.00596 USD |
| Cash Flow Per Share (Trailing Twelve Months) | -0.00262 USD |
| Free Cash Flow Per Share (Trailing Twelve Months) | -27610.21013 USD |
| Margins | |
|---|---|
| Cash Flow Revenue | |
| Cash Flow Revenue (5 Year) | -1,006 |
| Cash Flow Revenue (Trailing Twelve Months) | -100,000 |
| Pretax Margin | |
| Pretax Margin (Trailing Twelve Months) | -1,105.10% |
| Pretax Margin (Last Fiscal Year) | -1,027.46% |
| Pretax Margin (5 Year) | -1,105.36% |
| Gross Margin | |
| Gross Margin (Last Fiscal Year) | -99,999.99% |
| Gross Margin (Trailing Twelve Months) | -99,999.99% |
| Gross Margin (5 Year) | -99,999.99% |
| Operating Margin | |
| Operating Margin (Last Fiscal Year) | -1,102.96% |
| Operating Margin (Trailing Twelve Months) | -1,168.37% |
| Operating Margin (5 Year) | -1,101.31% |
| Net Profit Margin | |
| Net Profit Margin (Last Fiscal Year) | -1,027.46% |
| Net Profit Margin (Trailing Twelve Months) | -1,105.10% |
| Net Profit Margin (5 Year) | -1,105.36% |
| Growth | |
|---|---|
| Book Value | |
| Book Value Per Share (5 Year) | -42.75% |
| Tangible Book Value (5 Year) | 15.67% |
| Free Operating Cash Flow | |
| Free Operating Cash Flow (5 Year) | -99,999.99% |
| Revenue | |
| Revenue Change MRQ vs 1 Year Ago | -99,999.99% |
| Revenue Growth (3 Year) | -27.92% |
| Revenue Change (Trailing Twelve Months) | -99,999.99% |
| Revenue Per Share Growth | -64.15% |
| Revenue Growth (5 Year) | -0.88% |
| Capital Spending Debt | |
| Capital Spending (5 Year) | -42.92% |
| Total Debt (5 Year) | -99,999.99% |
| Dividends | |
| Dividend Growth (3 Year) | -99,999.99% |
| Earnings Per Share | |
| EPS Change MRQ vs 1 Year Ago | -99,999.99% |
| EPS Change (Trailing Twelve Months) | -99,999.99% |
| EPS Growth (3 Year) | -99,999.99% |
| EPS Growth (5 Year) | -99,999.99% |
| EBITDA | |
| EBITDA (5 Year) | -99,999.99% |
| EBITDA (5 Year Interim) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin Growth (5 Year) | -99,999.99% |
| Valuation | |
|---|---|
| Total Price to Book | |
| Price to Tangible Book (Last Fiscal Year) | 2 |
| Price to Tangible Book (Most Recent Quarter) | 6 |
| Price to Free Cash Flow | |
| Price to Free Cash Per Share (Last Fiscal Year) | -100,000 |
| Price to Free Cash Per Share (Trailing Twelve Months) | -100,000 |
| Net Debt | |
| Net Debt (Most Recent Quarter) | -17,122,920 |
| Net Debt (Last Fiscal Year) | -15,562,020 |
| Price to Sales | |
| Price to Sales (Last Fiscal Year) | 20 |
| Price to Sales (Trailing Twelve Months) | 23 |
| Price to Earnings | |
| PE Excluding Extraordinary Items (Last Fiscal Year) | -100,000 |
| PE Normalized (Last Fiscal Year) | -100,000 |
| PE Basic Excluding Extraordinary Items (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items High (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items Low (Trailing Twelve Months) | -100,000 |
| PE Including Extraordinary Items (Trailing Twelve Months) | -100,000 |
| Dividends | |
| Dividend Yield (5 Year) | -99,999.99% |
| Dividend Yield | -99,999.99% |
| Current Dividend Yield | 0.00% |
| Price to Book | |
| Price to Book (Last Fiscal Year) | 2 |
| Price to Book (Most Recent Quarter) | 6 |
| Financial Strength | |
|---|---|
| Debt to Equity | |
| Long Term Debt to Equity (Last Fiscal Year) | 0 |
| Long Term Debt to Equity (Most Recent Quarter) | 0 |
| Payout Ratio | |
| Payout Ratio (Last Fiscal Year) | -99,999.99% |
| Payout Ratio (Trailing Twelve Months) | -99,999.99% |
| Quick Ratio | |
| Quick Ratio (Last Fiscal Year) | -100,000 |
| Quick Ratio (Most Recent Quarter) | -100,000 |
| Enterprise Value | |
| Current Enterprise Value to Free Cash Flow (Last Fiscal Year) | -100,000 |
| Current Enterprise Value to Free Cash Flow (Trailing Twelve Months) | -100,000 |
| Current Ratio | |
| Current Ratio (Last Fiscal Year) | 5 |
| Current Ratio (Most Recent Quarter) | 3 |
| Free Cash Flow | |
| Free Cash Flow (Last Fiscal Year) | -30,573,550 |
| Free Cash Flow (Trailing Twelve Months) | -100,000 |
| Net Interest Coverage | |
| Net Interest Coverage (Last Fiscal Year) | -100,000 |
| Net Interest Coverage (Trailing Twelve Months) | -100,000 |
| Total Debt to Equity | |
| Total Debt to Equity (Last Fiscal Year) | 0 |
| Total Debt to Equity (Most Recent Quarter) | 0 |
| Management Effectiveness | |
|---|---|
| Return on Assets | |
| Return on Assets (Last Fiscal Year) | -79.22% |
| Return on Assets (Trailing Twelve Months) | -86.95% |
| Return on Assets (5 Year) | -102.29% |
| Return on Equity | |
| Return on Equity (Last Fiscal Year) | -142.49% |
| Return on Equity (Trailing Twelve Months) | -157.62% |
| Return on Equity (5 Year) | -189.99% |
| Return on Investment | |
| Return on Investment (Last Fiscal Year) | -103.51% |
| Return on Investment (Trailing Twelve Months) | -115.77% |
| Return on Investment (5 Year) | -131.07% |